期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小分子靶向药物治疗非小细胞肺癌的不良事件研究进展 被引量：5

原文传递
导出
摘要 目的:综述近年关于厄洛替尼和吉非替尼单用或合并用药研究中导致停药的主要不良反应及其用药的危险因素。方法:查阅、综述、分析近几年关于厄罗替尼和吉非替尼单用或合并用药在非小细胞肺癌治疗方面的研究文献。结果与结论:厄洛替尼和吉非替尼具有耐受性好且不良反应少等特点,但该类药物相关的不良事件依然应当受到关注。
作者 王晓辉 吴斌 朱珺
机构地区 上海交通大学医学院附属胸科医院药剂科 上海交通大学医学院附属仁济医院药剂科
出处 《中国药房》 CAS CSCD 北大核心 2011年第14期1329-1331,共3页 China Pharmacy
关键词 厄洛替尼 吉非替尼 非小细胞肺癌 不良反应
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1黄莹,张少军,李盈.治疗非小细胞肺癌的新药——吉非替尼[J].中国药房,2007,18(28):2219-2220. 被引量：5
  • 2杨迎暴,罗景慧.治疗非小细胞肺癌的新药——埃罗替尼[J].中国药房,2007,18(1):62-63. 被引量：3
  • 3Ando M,Okamoto I,Yamamoto N,et al.Predictive factorsfor interstitial lung disease,antitumor response,and sur-vival in non-small-cell lung cancer patients treated with gefitinib. Journal of Clinical Oncology . 2006 被引量：1
  • 4Fidler MJ,Argiris A,Patel JD,et al.The potential predic-tive value of cyclooxygenase-2expression and increased risk of gastrointestinal hemorrhagein advanced non-small-cell lung cancer patients treated with erlotinib and celecox-ib. Clinical Cancer Research . 2008 被引量：1
  • 5Wheatley-Price P,Ding K,Seymour L,et al.Erlotinib for advanced non-small-cell lung cancer in elderly:an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology . 2008 被引量：1
  • 6Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology . 2003 被引量：1
  • 7Shepherd FA,Pereira JR,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Homeopathy . 2005 被引量：1
  • 8Giaccone G,Herbst RS,Manegold C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 1. Journal of Clinical Oncology . 2004 被引量：1
  • 9Herbst RS,Giaccone G,Schiller JH,et al.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase Ⅲ trial-INTACT2. Journal of Clinical Oncology . 2004 被引量：1
  • 10Etienne-Grimaldi,MC,Pereira,S,Magne,N.Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Annals of Oncology . 2005 被引量：1

二级参考文献17

  • 1梅同华,徐小杰.TP与NP方案治疗晚期非小细胞肺癌的疗效比较[J].中国药房,2005,16(2):127-128. 被引量：15
  • 2Cohen MH,Johnson JR,Chen YF,et al.FDA drug approval summary:Erlotinib(Tarceva(R)) tablets[J].Oncologist,2005,10(7):461. 被引量：1
  • 3Tarceva[package insert][S].Melville,NY:OSI Pharmaceuticals,Inc,2005:1. 被引量：1
  • 4Pao W,Miller VA.Epidermal growth factor receptor mutations,small-molecule kinase inhibitors,and non -small-cell lung cancer:current knowledge and future direction[J].J Clin Oncol,2005,23(11):2 556. 被引量：1
  • 5Shepherd FA,Rodrigues PJ,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer[J].N Engl J Med,2005,353(2):123. 被引量：1
  • 6Perez-Soler R,Chachoua A,Hammond LA,et al.Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J].J Clin Oncol,2004,22(16):3 228. 被引量：1
  • 7Herbst RS,Johnson DH,Mininberg E,et al.Phase Ⅰ/Ⅱtrial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with non-small-cell lung cancer[J].J Clin Oncol,2005,23(11):2 544. 被引量：1
  • 8Herbst RS,Prager D,Hermann R,et al.TRIBUTE:A phase Ⅲ trial of erlotinib hydroehloride(OSI-7474)combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer[J].J Clin Oncol,2005,23(25):5 892. 被引量：1
  • 9Pao W,Miller VA.Epidermal growth factor receptor mutations,small-molecule kinase inhibitors,and non small-cell lung cancer:current knowledge and future direction[J].J Clin Oncol,2005,23(11):2 556. 被引量：1
  • 10Solomon B,Hagekyriakou J,Trivett MK,et al.EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing eadiation in human A431 squamous cell carcinoma[J].J Radiat Oncol Biol Phys,2003,55(3):713. 被引量：1

共引文献6

同被引文献76

  • 1王祥麒,王璇.脾肾双补法治疗伊立替康所致延迟性腹泻25例临床疗效观察[J].中医药学报,2011,39(4):118-119. 被引量：9
  • 2杨迎暴,罗景慧.治疗非小细胞肺癌的新药——埃罗替尼[J].中国药房,2007,18(1):62-63. 被引量：3
  • 3Robinson DM, Keating GM, Perry CM. Erlotinib[J].Am J Cancer, 2005,4 (4) : 247. 被引量：1
  • 4Siegel-Lakhai WS, Beijnen JH, Schellens JH.Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and zefitinib(Iressa) [J].Oncoloeist, 2005,10(8) : 579. 被引量：1
  • 5Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factorreceptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibitor [J]. J Clin Oncol, 2002,20(1) : 110. 被引量：1
  • 6Perez-soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer [J].Clin Lung Cancer, 2006,8(suppl 1 ) : S7. 被引量：1
  • 7Dancey J, Sausville EA. Issues and progress will protein kinase inhibitors for cancer treatment[J]. Nat Rev Drug Discov, 2003,2 : 296. 被引量：1
  • 8Lynch TJ Jr,Kim E,Eady B,et al.Epidermal growth factor receptor inhibitor-associated cutaneous toxicities:An evolving paradigm in clinical management[J].Oncologist,2007,12(5):610. 被引量：1
  • 9Ocvirk J,Cencelj S.Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer[J].J Eur Acad Dermatol Venereol,2010,24(4):453-459. 被引量：1
  • 10Jatoi A,Nguyen PL.Do patients die from rashes fromepidermal growth factor receptor inhibitors?A systematic review to help counsel patients about holding therapy[J].Oneologist,2008,13(11):1201-1204. 被引量：1

引证文献5

二级引证文献14

中国药房
2011年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部